Loading…
Medical-technology/distribution unit of the Xiamen C&D trading conglomerate; exact product scope not independently confirmed.
Medical-technology/distribution unit of the Xiamen C&D trading conglomerate; exact product scope not independently confirmed.
Moat: none
Headquarters: Xiamen, Fujian, China · Employees: 2,115
Size Shanghai C and D INNOSTIC Medical Technology (301584.SZ) is a China Health Care company (Medical Distributors) with a market value of $1.20B, the 1967th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥19.02 on 6 Nov 2026.
Performance Over six months the shares fell 27.5%, against -1.7% for the median peer and -16.4% for the China market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 8.4% over the last twelve months (peer median +4.6%); the operating margin is 3.1% (peer median 1.8%).
Valuation It trades at 0.6× enterprise value to sales against a peer median of 0.7× (10th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -19 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.9 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥19.9B | CN¥19.4B | CN¥17.9B | CN¥15.4B | CN¥11.9B |
| Revenue growth | — | +8% | +16% | +30% | — |
| Gross profit | CN¥1.62B | CN¥1.44B | CN¥1.25B | CN¥1.14B | CN¥864M |
| EBITDA | n/a | CN¥701M | CN¥646M | CN¥511M | CN¥364M |
| Net income | CN¥293M | CN¥270M | CN¥228M | CN¥196M | CN¥174M |
| Free cash flow | CN¥909M | CN¥668M | CN¥43.4M | -CN¥457M | -CN¥661M |
| Capital expenditure | CN¥72.6M | CN¥80.7M | CN¥121M | CN¥82.4M | CN¥33.5M |
| Total debt | CN¥4.67B | CN¥4.53B | n/a | CN¥3.87B | CN¥2.65B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301584.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.7% | +1.0% | 10th highest of 21 |
| 6-month return | -27.5% | -1.7% | 2nd lowest of 21 |
| Distance from 52-week high | -53.4% | -18.4% | lowest of 21 |
| Revenue growth (TTM) | +8.4% | +4.6% | 7th highest of 21 |
| Operating margin | 3.1% | 1.8% | 9th highest of 21 |
| EV / Sales | 0.6× | 0.7× | 10th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | -1.3% | -1.1% | 8th least demanding of 17 |
| Growth delivered (Del g) | +17.9% | +5.5% | 2nd highest of 17 |
| Hurdle (Req g minus delivered) | -19.2 pp | -7.2 pp | 2nd least demanding of 17 |
| ROIC minus cost of capital | +3.9 pp | +0.6 pp | 3rd highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.20B | -28% | +8% | 3% | 0.6× | -1.3% | +17.9% |
| Shinva Medical Instrument 600587.SS | China | $1.16B | -7% | +6% | 5% | 0.7× | -5.9% | +1.2% |
| Ship Healthcare 3360.T | Japan | $1.34B | +4% | +7% | 3% | 0.2× | -14.7% | +7.6% |
| AS ONE 7476.T | Japan | $1.08B | +15% | +10% | 12% | 1.3× | -1.0% | +6.3% |
| Nanjing Pharmaceutical 600713.SS | China | $1.03B | +1% | +3% | 2% | 0.3× | n/a | n/a |
| DocMorris DOCM.SW | Switzerland | $1.02B | +136% | +11% | -8% | 0.9× | n/a | n/a |
| Arjo ARJO-B.ST | Sweden | $1.02B | +48% | 0% | 8% | 1.3× | -1.3% | +3.9% |
| Guangxi LiuYao 603368.SS | China | $994M | +2% | +2% | 5% | 0.4× | -9.5% | +6.0% |
| Shanghai Haohai Biological Technology 688366.SS | China | $946M | -24% | -9% | -2% | 2.0× | 18.9% | +13.2% |
| Toho 8129.T | Japan | $1.60B | -14% | +4% | 1% | 0.1× | -7.4% | +5.1% |
| Redcare Pharmacy RDC.DE | Germany | $1.63B | +52% | +19% | 0% | 0.5× | n/a | n/a |
| Entero Healthcare Solutions ENTERO.NS | India | $875M | +50% | +32% | 4% | 1.2× | 21.8% | +29.9% |
| Neuca NEU.WA | Poland | $817M | -1% | +8% | 2% | 0.3× | 5.0% | +8.1% |
| Suzuken 9987.T | Japan | $2.29B | -9% | +5% | 1% | 0.1× | -11.9% | +3.2% |
| Shanghai New World 600628.SS | China | $623M | -11% | -2% | 6% | 2.4× | 0.3% | +1.0% |
| GKHT Medical Technology 301370.SZ | China | $569M | -22% | -11% | 1% | 0.8× | 14.4% | +7.5% |
| Arata 2733.T | Japan | $552M | -7% | +3% | 1% | 0.1× | -7.1% | +3.8% |
| Hanmi Science 008930.KS | South Korea | $2.71B | +44% | +6% | 5% | 2.6× | 24.2% | +9.6% |
| Alfresa 2784.T | Japan | $2.79B | -3% | +5% | 1% | 0.1× | -9.1% | +3.5% |
| Shanghai Lily & Beauty Cosmetics 605136.SS | China | $517M | -21% | +10% | 0% | 1.2× | 12.2% | -18.1% |
| Thalys Medical Technology 603716.SS | China | $501M | -29% | -41% | -17% | 4.1× | n/a | n/a |